Treatment of necrobiosis lipoidica with secukinumab (Cosentyx): a case series Dear Editor, Necrobiosis lipoidica (NL) is a chronic granulomatous disease with no current Food and Drug Administration-approved treatment. Previous published treatments have been small and inconsistent. IL-17 has been implicated in the pathogenesis of NL. 1 We report the use of secukinumab, a monoclonal antibody against IL-17A, for treating NL. Patients enrolled from April 3, 2019, to April 15, 2021, in an open label, proof of concept study (terminated early due to low enrollment during the COVID-19 pandemic). Inclusion criteria included age ≥18, history of biopsy-proven NL, and active NL lesions defined as clinical signs of inflammation or new/expanding lesions. Patients received secukinumab 300 mg subcutaneously weekly for 5 weeks then every 4 weeks for a total of 24 weeks. The primary endpoint was NL Investigator Global from the corresponding author, MP, upon reasonable request.

No abstract

No abstract

Coccygeal polypoid eccrine nevi (CPEN) are rare, benign, cutaneous polypoid lesions localized to the coccyx region that are characterized by areas of hyperplastic eccrine ducts without hyperhidrosis. We present the case of an asymptomatic 16-month-old female with a congenital lesion in the lower sacral area and review the literature and the differential diagnosis for CPEN.

No abstract